跳至主要内容
临床试验/NCT03687905
NCT03687905Unknown不适用

Comparative Study Between Chloroquine and Hydroxychloroquine as Therapeutic Modalities for Children and Adolescents With Proliferative Lupus Nephritis

Tanta University1 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2018年9月18日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
入组人数
60
试验地点
1
主要终点
Fundus examination as screening test

研究概览

简要总结

Evaluation the efficacy of chloroquine and hydroxychloroquine in the treatment of proliferative lupus nephritis class III and IV in children and adolescents and evaluate the side effects of both drugs .

详细描述

All patients will fulfill the diagnostic criteria of SLE. The diagnosis of systemic lupus erythematosus is based on clinical and laboratory criteria. The criteria set developed by the American College of Rheumatology (ACR) and diagnosed wih lupus nephritis class III and IV .

Inclusion Criteria:

  • Children and adolescents who fulfill diagnostics criteria of SLE and diagnosed with lupus nephritis class III and IV.
  • All patients will be received steroids , MMF and Angiotensin Converting Enzyme.

Exclusion Criteria:

  • Patients diagnosed with lupus nephritis class I,II,V and VI.
  • Patients received Cyclophosphamide in stead of MMF.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
10 Years 至 18 Years(Child, Adult)
性别
All
接受健康志愿者

入选标准

  • Children and adolescents who fulfill diagnostics criteria of SLE and diagnosed with lupus nephritis class III and IV.
  • All patients will be received steroids , MMF and Angiotensin Converting Enzyme.

排除标准

  • Patients diagnosed with lupus nephritis class I,II,V and VI.
  • Patients received Cyclophosphamide in stead of MMF.

研究组 & 干预措施

Lupus nephritis III or IV/chloroquine

receiving chloroquine with daily dose 5 mg/kg

干预措施: Chloroquine (Drug)

Lupus nephritis III or IV/hydroxychloroquine

receiving hydroxycholorquine with daily dose 5 mg/kg

干预措施: Hydroxychloroquine (Drug)

结局指标

主要结局

Fundus examination as screening test

时间窗: 12 months

Detection of chloroquine and hydroxychloroquine related retinal toxicity at early stage.

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Fatma Sayed Ahmed Gheet

Resident Pediatercian

Tanta University

研究点 (1)

Loading locations...

相似试验